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Abstract
For decades, non-human primates (NHPs) have been employed as experimental models 
to study many aspects of human diseases. They are the closest genetically to humans 
of any of the models applied in biomedical research; therefore, many authors have 
published scientific work regarding these animals and infectious diseases, including 
tuberculosis, AIDS, and tropical diseases. Among these, Chagas disease has caught the 
attention of many researchers all over the world. Recent studies have demonstrated great 
similarities with the human pathology, including cardiomyopathy and exacerbated pro-
inflammatory response. Besides being genetically close to humans, NHP have a great 
probability to be naturally infected by Trypanosoma cruzi, which turns them into more 
interesting models to study Chagas disease mechanisms.
Keywords: non-human primates, Chagas disease, T. cruzi, immunology, infectious 
diseases
1. Introduction
The haemoflagellate Trypanosoma cruzi causes Chagas disease, one of the most relevant 
neglected tropical diseases of humankind. The World Health Organization estimates that 
there are 6–7 million people infected over the world [1–3] as shown in Figure 1. Nevertheless, 
other mammals are also at risk of becoming infected, such as marsupials, armadillos, syl-
vatic and domestic dogs, racoons and non-human primates (NHPs) [4–8]. The most com-
mon Chagas disease transmission is the vectorial via by several species of triatomine. The 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
vector insect ingests a blood meal containing bloodstream trypomastigotes which later, in 
the insect’s gut, the parasite differentiates into epimastigotes and replicates. When the vector 
defecates, metacyclic trypomastigote forms are released and invade the host through bro-
ken skin or mucosal membranes. A brief schematic mechanism of T. cruzi infection is shown 
Figure 1. Descriptive map of infection areas in the world.
Figure 2. Schematic life cycle of Trypanosoma cruzi.
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in Figure 2. In addition, the oral and congenital transmissions are other important ways of 
becoming infected [6]. Out of these, the oral transmission seems more relevant, especially by 
non-human species. The habit of consuming bugs may predispose these animals to ingest 
infected triatomines [9]. Amongst the non-human species presented above, non-human pri-
mates are the greatest species comparable to human beings, leading researchers all over the 
world to employ NHP in biomedical-related studies. Interestingly, Carlos Chagas was the 
first to describe both experimental and natural T. cruzi infections in non-human primates [10]. 
After that, many others have portrayed the disease in these animals, and studies are still being 
produced nowadays. From small college laboratories to huge pharmaceutical industries, the 
purpose is the same: to find better options to diagnose and to treat patients. Our group has 
been working with NHP for a few years, and so far, our findings are similar to those from 
many researchers all over the world. The aim of this work is to explore the most relevant find-
ings regarding T. cruzi-infected NHP.
2. Clinical manifestations of NHP T. cruzi infection
Several studies have demonstrated that NHP develop clinical manifestations highly similar 
to what is observed in both acute and chronic human Chagas disease [9, 11–14]. In the acute 
phase, several signs and symptoms can be observed, such as inoculation chagoma, patent 
parasitemia, T. cruzi-specific IgM and IgG antibodies, and leukocytosis and lymphocytosis. 
Histopathological data revealed intense heart parasitism and pronounced inflammatory infil-
trate, along with myocardial fibrosis with collagen deposits [12]. Besides that, cardiac altera-
tions have also been found in these animals, such as abnormal electrocardiogram and heart 
muscle cells presenting degrees of damage [13]. Those findings reinforce the results found 
by Bonecini-Almeida et al. [11] who described electrocardiographic patterns detected in 
T. cruzi-infected rhesus monkeys during the acute phase. The results have evidenced atrio-
ventricular block, right bundle branch block—first-degree His bundle, low voltage QRS com-
plex, and abnormal ventricular repolarization. Interestingly, these alterations disappeared at 
the fourth month post infection. Controversially, Bommineni et al. [14] demonstrated that 
the acute phase in NHP may be lethal. Despite that, T. cruzi infection usually evolves from an 
acute phase to a chronic phase that may manifest itself in a variety of ways.
In contrast to the acute phase, during the chronic stages of the disease, the trypomastigotes in the 
peripheral circulation are extremely difficult to detect microscopically. However, more detailed 
histopathological studies have shown nests of T. cruzi amastigote forms in host cardiac tissue 
from naturally infected baboons. The majority of individuals that progress to the chronic phase 
remain clinically asymptomatic for many years, characterizing the indeterminate clinical form 
of the disease. Usually the disease confirmation requires the application of several diagnostic 
techniques, such as microscopic examination of blood smears, serological assays, xenodiagno-
sis, hemoculture and PCR-based assays for direct detection and quantification of parasite DNA 
[15–17]. After long years of infection, individuals may progress to the cardiac and/or digestive 
chronic phase, which usually represents the most severe clinical damages [18]. Researchers have 
demonstrated numerous alterations in the electrical conduction system, ventricular arrhythmias, 
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cardiomegaly, enteromegaly, myocardial fibrosis, and edema, along with other clinical signs of 
chronicity [9, 12, 13, 19, 20]. In several cases the infected NHP develop aggressive chronic Chagas 
disease and die, usually due to cardiac damages. In this context, a NHP animal model with these 
features could contribute significantly to better comprehend the disease outcome as well as to 
improve the therapies for Chagas disease.
3. Immunological features of NHP T. cruzi infection
In addition to pathophysiological changes, NHP also manifest alterations in their immuno-
logical system. It is well known that the immune system plays an important role in the patho-
genesis of the disease. When it comes to NHP, it is not different. Recent studies, including 
ours, have shown that their immunological response resembles what is observed in human 
Chagas disease, as briefly schemed in Figure 3 [1, 6, 18, 21].
Figure 3. Trypanosoma cruzi naturally infected non-human primate displays, in the peripheral blood, a high activity 
of cytotoxic cells (Granzyme A+ NK cells and Granzyme A+/Perforin CD8+ T cells) and expansion of macrophages and 
activated T-cell subsets. Furthermore, the infected animals exhibit an overall mixed pro-inflammatory/regulatory 
cytokine milieu, with CD4+ T cells, the most important source of IFN-γ, as well as CD4+ T cells, CD8+ T cells, macrophage/
monocytes and B-cell producers of IL-10.
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Our group has recently published a research on T. cruzi naturally infected cynomolgus 
macaques which displayed, in the peripheral blood, a similar immunological profile to that 
observed in humans, with high activity of cytotoxic cells and expansion of macrophages and 
activated T-cell subsets [21]. The infected animals exhibit higher frequency of NK Granzyme 
A+ cells. Furthermore, this cell population was able to increase the pro-inflammatory cytokine 
secretion afterwards T. cruzi antigen stimulation [22]. These data reinforce the important role 
of NK cells as a source of IFN-γ to activate macrophages and increase the nitric oxide pro-
duction to inhibit the intracellular parasite growth [23, 24]. Moreover, the NK cells mediate a 
relevant cytotoxic mechanism that kill infected host cells or even free parasites throughout a 
lytic perforin-independent mechanism [24]. It is important to mention that the higher expres-
sion of inducible nitric oxide synthase by monocytes/macrophage has been correlated with 
loss of connexin43 in cardiopathic T. cruzi-infected rhesus monkeys [12]. Connexin43 is the 
major protein responsible for the electrical synchrony of cardiomyocytes [25]. In this context, 
any injury in this protein may result in arrhythmias and heart failure during the chronic cha-
gasic cardiomyopathy.
It is well known that the adaptive immune response plays a critical role in Chagas disease 
progression in humans; however, in NHP its mechanisms remain unclear. Recently, our 
group showed that the T. cruzi-infected NHP developed a pattern of activated T lymphocytes 
as observed in the human infection. In fact, higher expression of CD54 and HLA-DR by T 
cells, especially within the CD8+ subset, along with outstanding expression of Granzyme A 
and Perforin, emphasized the enhanced cytotoxicity-linked pattern of CD8+ T lymphocytes. 
These data reinforce the role of CD8+ T lymphocytes in the pathogenesis of Chagas disease. 
Additionally, Pisharath et al. [6] while evaluating T. cruzi naturally infected cynomolgus 
macaques demonstrated by immunohistochemistry that the inflammatory infiltrate from 
cardiac tissue had mild to moderate multifocal areas, composed predominantly by CD8+ T 
cells and CD68+ monocyte/macrophage with fewer CD4+ T lymphocytes. In agreement with 
these data, Mubiru et al. [20] showed a focal and multifocal collection of lymphocytes and 
plasma cells, as well as rare granulocyte infiltration within the myocardium and epicardium. 
Moreover, their study revealed a positive correlation between PCR positivity and lympho-
cytic myocarditis in both baboons and cynomolgus macaques infected with T. cruzi, reinforc-
ing the hypothesis of direct parasite-induced damage and T. cruzi-specific immune responses, 
in myocardial injury.
It is known that B lymphocytes play a crucial role in protecting against T. cruzi. This is due 
to the fact that these cells synthesize anti-T. cruzi antibodies, establish the functional pattern 
of T-cell cytokines and still are involved in the maintenance of CD8+ memory cells [26, 27]. In 
addition, it has been displayed that NHP infected with T. cruzi presents a high frequency of 
B-cell population associated with upregulated expression of Fc-γRII (CD32), enhancing the 
potential of this biomarkers’ high expression, in counterbalancing the CD8+ T-cell cytotoxic 
activity and influencing the degree of myocardiopathy.
It has been clear that cytokines are integral components of the complex intercellular system 
required to mount and control disease morbidity [28, 29]. However, little is known about 
the cytokine profile during NHP infection with T. cruzi. In order to further understand the 
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mechanisms of T. cruzi infection in NHP, Vitelli-Avelar [22], for the first time, characterized 
the ex vivo cytokine pattern of cynomolgus macaques naturally infected with T. cruzi and 
observed an overall mixed pro-inflammatory/regulatory cytokine milieu, mediated by IFN-γ 
from CD4+ T cells counterbalanced by IL-10 produced by CD4+ T cells and B cells. This micro-
environment resembles that previously described for chronic Chagas disease in humans, 
mainly in indeterminate clinical form [24]. It has been proposed that this pro-inflammatory/
regulatory pattern represents a key element to control deleterious antiparasite immune-medi-
ated inflammatory mechanisms [30].
T. cruzi strains are currently classified into six discrete typing units (DTUs) named TcI to 
TcVI. It is known that these DTUs have different biological and geographical features [31]. In 
South American isolates, all of the strains have been characterized from a variety of host spe-
cies. In contrast, isolates from the Central and North America have been characterized only 
as TcI or TcIV [32]. Several researchers have discussed the characteristics of different T. cruzi 
genotypes, and it seems like that the strain diversity is associated with the distinct immuno-
logical patterns observed in Chagas disease, which might be associated to disease severity [31, 
33–36]. While working with a North American NHP colony, we intended to provide insights 
pertinent to the higher prevalence of TcI natural infection observed amongst these animals 
by interpreting the differential impact of TcI and TcIV antigen priming in vitro on circulat-
ing leukocytes. In this context, our data showed that NHP presents distinct cytokine profile 
in the presence of TcI and TcIV antigen. While the TcIV antigen triggered an outstanding 
response, characterized by high levels of TNF- and IFN-γ-producing CD8+ T cells, along with 
low levels of IL-10, the TcI antigen elicits a predominant regulatory microenvironment, medi-
ated by IL-10 derived from HLA-DR++ monocytes and T cells with low levels of TNF+CD8+ T 
cells [22]. The prominent pro-inflammatory milieu, mediated by TNF, seems to be relevant 
to control the T. cruzi infection NHP. The role of TNF in protective mechanisms has been 
already reported, underscoring its ability to activate macrophages and induce nitric oxide 
production [37]. Additionally, the enhanced frequency of IFN-γ+ T cells beside low levels of 
IL-10-producing cells may also account as a relevant trypanocidal event favoring the TcIV 
clearance. Conversely, the IL-10-mediated microenvironment observed upon TcI-antigenic 
recall in vitro represents a critical event to support the ongoing infection with the TcI geno-
type. These findings may support, at least in part, the predominance of TcI infection amongst 
cynomolgus macaques in Southern part of the United States. Figures 4 and 5 present a syn-
thesized scheme of our newest cytokine findings and reinforce the distinct cytokine pattern 
produced upon T. cruzi TcI and TcIV antigen recall in vitro [22]. Furthermore, other studies 
have confirmed the presence of both TcI and TcIV isolates from Amazonian primates, TcI 
being more predominate strain than TcIV [38–40].
Regardless the relevance of therapeutic intervention to control morbidity and clinical pro-
gression of Chagas disease, currently, there are only two drugs available to treat infected 
hosts, benznidazole and nifurtimox. Several studies have demonstrated that the effective-
ness of therapeutic agents against T. cruzi is influenced by the parasite load, genotype as 
well as by intrinsic features of the host immune response. Studies focusing on aspects related 
to the synergic effect of the immune response and chemotherapeutic agents in humans and 
NPH are still scarce. Sathler-Avelar and colleagues [21, 22, 24] have provided insights about 
Primates136
the relevance of a balanced immune response elicited after chemotherapeutic intervention to 
mediated parasite killing but minimize tissue damage. There are evidences supporting that a 
pro-inflammatory response mediated by IFN-γ acts synergistically with the drug treatment 
to accomplish effective trypanocidal events [24, 41] and that simultaneous regulatory mecha-
nisms elicited by IL-10 are relevant to control deleterious effects of therapeutic intervention 
[21, 22, 24].
The urgent need of novel drugs to treat Chagas disease has stimulated scientific community to 
validate appropriate experimental model or in vitro tolls to conducted studies during preclini-
cal trials. These studies that can contribute and elucidate drug mechanisms are still unknown, 
in an attempt to find a more effective therapeutic agent. In this context, NHP models have 
been considered one of the most appropriate tolls, especially due to the similarities between 
the disease aspects and the immune response observed in NPH as compared to humans. 
Vitelli-Avelar and colleagues have recently provided data focusing on the immune response 
of NPH infected with T. cruzi that can be used to shed light on this issue. Using an in vitro 
system of antigen recall to mimicry the endogenous booster of parasite-derived antigens that 
Figure 4. The cytokine milieu in T. cruzi-infected and non-infected non-human primates upon antigen recall from TcI and 
TcIV T. cruzi strain. The radar charts illustrate the changes on the pro-inflammatory (black background) and regulatory 
cytokine microenvironment (gray background) connecting circulating leukocytes of T. cruzi-infected cynomolgus 
macaques (CH) and non-infected controls (NI) upon TcI (A) and TcIV (B) T. cruzi antigenic recall in vitro. Relevant data 
comprising biomarkers with frequency of producers above the 50th percentile are underscored by bold/underlined font.
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occur throughout chronic infection or upon the extensive antigen release mediated by thera-
peutic intervention, these authors have demonstrated that similarly to what was found in 
human Chagas disease patients, NPH-infected host also exhibited a pro-inflammatory/regu-
latory cytokine signature triggered by T. cruzi-antigenic restimulation in vitro, These findings 
suggest the ability of these hosts to mount an appropriate immune response with putative 
balanced profile that may contribute for parasite killing, by IFN-γ release, modulated by IL-10 
to prevent deleterious idiosyncrasy.
4. Final remarks
The urge for an experimental model that resembles all medical disorders observed in humans 
is of great importance. Non-human primates are great models to study Chagas disease. It is 
clear that these mammals present clinical, immunological, and histopathological resemblances 
to humans. All studies conducted so far lead to believe that as shown in humans, primates 
Figure 5. Cytokine network analysis upon T. cruzi antigen (TcI/TcIV) stimulation in vitro. Correlation matrices for 
cytokine producers were constructed to illustrate the distinct cytokine pattern upon (A) TcI and (B) TcIV antigen 
stimulation. Cytokine+ cell networks for non-human primate naturally infected with T. cruzi (CH) and control animals 
(NI) are shown by clustered distribution of nodes for pro-inflammatory (black) and modulatory (gray) cytokine patterns.
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naturally infected with T. cruzi also evolve to chronic phase and that is probably associated to 
the extension of the immune response they develop. With an experimental model that devel-
ops clinical and immunological manifestations closely comparable to humans, innovative 
therapeutic strategies may be deeper studied and new drugs may be developed. There are still 
much more to comprehend; however, the scientific advances and better comprehension of the 
mechanisms of T. cruzi infection may contribute to find hope to Chagas disease patients.
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